Research ArticleOpen AccessGoogle Scholar indexed
Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma
Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Laboratory of Genetic Biotechnology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Department of Bone Marrow Transplantation, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
- 1 Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
- 2 Laboratory of Genetic Biotechnology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
- 3 Department of Bone Marrow Transplantation, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
- 4 Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Journal of Cancer Therapy·Volume 08 (2017)·Pages 683–690·Published 27 July 2017·DOI10.4236/jct.2017.88059
Copy link · social · email
Abstract
Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRD- positive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.
KeywordsAnaplastic Large Cell LymphomaRelapseBrentuximab VedotinDonor Lymphocyte InfusionMinimal Residual Disease
- Brugières, L., Le Deley, M.C., Rosolen, A., Williams, D., Horibe, K., Wrobel, G., Mann, G., Zsiros, J., Uyttebroeck, A., Marky, I., Lamant, L. and Reiter, A. (2009) Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents with Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group. Journal of Clinical Oncology, 27, 897-903. https://doi.org/10.1200/JCO.2008.18.1487
- Lowe, E.J., Sposto, R., Perkins, S.L., Gross, T.G., Finlay, J., Zwick, D., Abromowitch, M. and Children’s Group Study 5941 (2009) Intensive Chemotherapy for Systemic Anaplastic Large Cell Lymphoma of Children and Adolescents: Final Results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer, 52, 335-339. https://doi.org/10.1002/pbc.21817
- Rosolen, A., Pillon, M., Garaventa, A., Burnelli, R., d’Amore, E.S., Giuliano, M., Comis, M., Cesaro, S., Tettoni, K., Moleti, M.L., Tamaro, P., Visintin, G. and Zanesco, L. (2005) Anaplastic Large Cell Lymphoma Treated with a Leukemia-Like Therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 Protocol. Cancer, 104, 2133-2140. https://doi.org/10.1002/cncr.21438
- Damm-Welk, C., Busch, K., Burkhardt, B., Schieferstein, J., Viehmann, S., Oschlies, I., Klapper, W., Zimmermann, M., Harbott, J., Reiter, A. and Woessmann, W. (2007) Prognostic Significance of Circulating Tumor Cells in Bone Marrow or Peripheral Blood as Detected by Qualitative and Quantitative PCR in Pediatric NPM-ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 110, 670-677. https://doi.org/10.1182/blood-2007-02-066852
- Damm-Welk, C., Mussolin, L., Zimmermann, M., Pillon, M., Klapper, W., Oschlies, I., d’Amore, E.S., Reiter, A., Woessmann, W. and Rosolen, A. (2014) Early Assessment of Minimal Residual Disease Identifies Patients at Very High Relapse Risk in NPM-ALK-Positive Anaplastic Large-Cell Lymphoma. Blood, 123, 334-337. https://doi.org/10.1182/blood-2013-09-526202
- Woessmann, W., Zimmermann, M., Lenhard, M., Burkhardt, B., Rossig, C., Kremens, B., Lang, P., Attarbaschi, A., Mann, G., Oschlies, I., Klapper, W. and Reiter, A. (2011) Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents after Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study. Journal of Clinical Oncology, 29, 3065-3071. https://doi.org/10.1200/JCO.2011.34.8417
- Theurich, S., Malcher, J., Wennhold, K., Shimabukuro-Vornhagen, A., Chemnitz, J., Holtick, U., Krause, A., Kobe, C., Kahraman, D., Engert, A., Scheid, C., Chakupurakal, G., Hallek, M. and von Bergwelt-Baildon, M. (2013) Brentuximab Vedotin Combined with Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma after Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. Journal of Clinical Oncology, 31, e59-63. https://doi.org/10.1200/JCO.2012.43.6832